Delayed Emergence
Conditions
Interventions
Infusion Group:Esketamine was intravenous infused at a dose of 0.5 mg/kg during the operation.
Induction Group:Intravenous esketamine (0.5 mg/kg) was administered at anesthesia induction.
Control Group:Normal saline was administered at a volume equivalent to the study groups during induction and intraoperatively.
Sponsors
The Third Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18 to 65 years; 2.Body Mass Index (BMI): 18.5 to 30.0 kg/m^2; 3.American Society of Anesthesiologists (ASA) physical status classification: Class I or II; 4.Scheduled for elective laparoscopic gynecological surgery and voluntarily provided signed informed consent; 5.No history of allergy to esketamine or other anesthetic agents; 6.Willingness to use Patient-Controlled Intravenous Analgesia (PCIA).
Exclusion criteria
Exclusion criteria: 1.A history of psychiatric disorders or neurological diseases, or a history of alcohol or substance abuse; 2.An inability to communicate due to language barriers and/or sensory impairments (e.g., hearing, vision), preoperative cognitive dysfunction (defined as a Mini-Mental State Examination (MMSE) score of 7; 5.A history of surgery within one month prior to the study or the use of any medications that may affect the central nervous system (such as sedative-hypnotics, opioids, antidepressants, antipsychotics, or anxiolytics) within one week prior to surgery; 6.pregnancy or lactation; 7.Cardiac insufficiency, uncontrolled ischemic heart disease, arrhythmia from any cause, or uncontrolled hypertension (systolic blood pressure >=140 mmHg and/or diastolic blood pressure >=90 mmHg); 8.Severe obstructive sleep apnea (indicated by a STOP-Bang questionnaire score >= 5); 9.Conditions for which esketamine is clearly contraindicated, such as hyperthyroidism, pheochromocytoma, or significantly elevated intracranial or intraocular pressure; 10.Severe hepatic or renal dysfunction; 11. Participation in other clinical trials or previous enrollment in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recovery time of consciousness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery time of breath;PACU length of stay ;Postoperative 24-hour pain intensity;Patient's postoperative awakening status and recovery quality;Postoperative fatigue level;Postoperative sleep quality;Postoperative mental status;Quality of Postoperative Recovery;Incidence of postoperative nausea and vomiting (PONV);Intraoperative hemodynamic stability of the patient;Intraoperative hemodynamic stability of the patient; | — |
Countries
China
Contacts
Public ContactChangsheng Li
The Third Affiliated Hospital of Zhengzhou University
Outcome results
None listed